KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Stryker (SYK) EBITDA (2016 - 2025)

Historic EBITDA for Stryker (SYK) over the last 17 years, with Q4 2025 value amounting to $1.8 billion.

  • Stryker's EBITDA rose 21049.91% to $1.8 billion in Q4 2025 from the same period last year, while for Dec 2025 it was $4.9 billion, marking a year-over-year increase of 3252.91%. This contributed to the annual value of $4.9 billion for FY2025, which is 3252.91% up from last year.
  • As of Q4 2025, Stryker's EBITDA stood at $1.8 billion, which was up 21049.91% from $1.1 billion recorded in Q3 2025.
  • Stryker's 5-year EBITDA high stood at $1.8 billion for Q4 2025, and its period low was $447.0 million during Q1 2022.
  • For the 5-year period, Stryker's EBITDA averaged around $894.6 million, with its median value being $828.0 million (2021).
  • Its EBITDA has fluctuated over the past 5 years, first surged by 376000.0% in 2021, then plummeted by 5377.88% in 2024.
  • Stryker's EBITDA (Quarter) stood at $819.0 million in 2021, then fell by 0.61% to $814.0 million in 2022, then soared by 54.42% to $1.3 billion in 2023, then crashed by 53.78% to $581.0 million in 2024, then soared by 210.5% to $1.8 billion in 2025.
  • Its EBITDA was $1.8 billion in Q4 2025, compared to $1.1 billion in Q3 2025 and $1.1 billion in Q2 2025.